AU2002329557B2 - 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists - Google Patents

3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists Download PDF

Info

Publication number
AU2002329557B2
AU2002329557B2 AU2002329557A AU2002329557A AU2002329557B2 AU 2002329557 B2 AU2002329557 B2 AU 2002329557B2 AU 2002329557 A AU2002329557 A AU 2002329557A AU 2002329557 A AU2002329557 A AU 2002329557A AU 2002329557 B2 AU2002329557 B2 AU 2002329557B2
Authority
AU
Australia
Prior art keywords
exo
aza
ethyl
hydroxy
hex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002329557A
Other languages
English (en)
Other versions
AU2002329557A1 (en
Inventor
Steven Donald Heck
Spiros Liras
Stanton Furst Mchardy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2002329557A1 publication Critical patent/AU2002329557A1/en
Application granted granted Critical
Publication of AU2002329557B2 publication Critical patent/AU2002329557B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002329557A 2001-10-22 2002-09-09 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists Ceased AU2002329557B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33851101P 2001-10-22 2001-10-22
US60/338,511 2001-10-22
PCT/IB2002/003668 WO2003035622A1 (en) 2001-10-22 2002-09-09 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists

Publications (2)

Publication Number Publication Date
AU2002329557A1 AU2002329557A1 (en) 2003-07-03
AU2002329557B2 true AU2002329557B2 (en) 2008-07-31

Family

ID=23325099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002329557A Ceased AU2002329557B2 (en) 2001-10-22 2002-09-09 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists

Country Status (42)

Country Link
US (3) US7049335B2 (enExample)
EP (1) EP1440059B1 (enExample)
JP (2) JP4155522B2 (enExample)
KR (1) KR100621292B1 (enExample)
CN (1) CN100368398C (enExample)
AP (1) AP1816A (enExample)
AR (1) AR036905A1 (enExample)
AT (1) ATE392415T1 (enExample)
AU (1) AU2002329557B2 (enExample)
BR (1) BR0213464A (enExample)
CA (1) CA2463264C (enExample)
CR (1) CR7317A (enExample)
DE (1) DE60226161T2 (enExample)
DK (1) DK1440059T3 (enExample)
EA (1) EA006708B1 (enExample)
EC (1) ECSP045077A (enExample)
ES (1) ES2302839T3 (enExample)
GE (1) GEP20084300B (enExample)
GT (1) GT200200216A (enExample)
HN (1) HN2002000299A (enExample)
HR (1) HRP20040288A2 (enExample)
HU (1) HUP0401884A2 (enExample)
IL (2) IL161157A0 (enExample)
IS (1) IS7187A (enExample)
MA (1) MA27141A1 (enExample)
MX (1) MXPA04003730A (enExample)
MY (1) MY136580A (enExample)
NO (1) NO329092B1 (enExample)
NZ (1) NZ531807A (enExample)
OA (1) OA12711A (enExample)
PA (1) PA8556701A1 (enExample)
PE (1) PE20030610A1 (enExample)
PL (1) PL368919A1 (enExample)
PT (1) PT1440059E (enExample)
PY (1) PY0225353A (enExample)
RS (1) RS25104A (enExample)
SI (1) SI1440059T1 (enExample)
SV (1) SV2004001363A (enExample)
TN (1) TNSN04071A1 (enExample)
UA (1) UA75714C2 (enExample)
WO (1) WO2003035622A1 (enExample)
ZA (1) ZA200402172B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
EP1675829A1 (en) * 2003-10-16 2006-07-05 Pfizer Products Inc. Preparation of 3-azabicyclo [3.1.0] hexane derivatives
ATE451364T1 (de) 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AU2005219785B2 (en) * 2004-03-05 2010-05-27 Msd K.K. Cycloalkanopyridine derivative
EP1837022A4 (en) * 2004-12-14 2009-12-16 Toray Industries INDOLOMORPHINANE DERIVATIVE WITH CARBOXY IN 6 'POSITION
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2009029253A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
CA2927527C (en) * 2013-11-20 2021-06-01 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
HK1246778A1 (zh) * 2015-05-20 2018-09-14 株式会社三和化学研究所 一种新型的3-氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用
EP3590511A4 (en) 2017-03-02 2020-09-02 Sanwa Kagaku Kenkyusho Co., Ltd THERAPEUTIC AGENT FOR DISORDERS RELATED TO THE CONSUMPTION OF ALCOHOL

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039089A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands
WO2001098267A1 (en) * 2000-06-23 2001-12-27 Pfizer Limited 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099214A (en) * 1937-11-16 Process fob forming the sulphuric
US2099216A (en) * 1934-05-04 1937-11-16 Frederick H Nass Metal testing machine
US3004340A (en) * 1959-09-24 1961-10-17 Bernice L Collins Kitchen utensil
US3078282A (en) * 1960-01-02 1963-02-19 Bayer Ag Anthraquinone dyestuffs
ATE110057T1 (de) 1987-04-16 1994-09-15 Lilly Co Eli Piperidine als opioid-antagoniste.
JPH04155522A (ja) * 1990-10-19 1992-05-28 Nec Corp ファースト・イン・ランダム・アウト回路
ZA922180B (en) 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20020064825A1 (en) * 2000-05-19 2002-05-30 Lewis Marilyn Evelyn Novel polypeptide
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
DE10042885A1 (de) * 2000-08-31 2002-03-14 Heidelberger Druckmasch Ag Bogentransportzylinder
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
AU2003239389A1 (en) 2002-05-30 2003-12-19 Eli Lilly And Company Opioid receptor antagonists
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039089A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands
WO2001098267A1 (en) * 2000-06-23 2001-12-27 Pfizer Limited 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Beck A. L., et al, J. Chem. Soc. Perkin Trans. 1, 1990, pages 689-693. *
Campbell M. M., et al, Tetrahedron, vol. 41, no. 23, 1985, pages 5637-5644. *
Mosettig E., et al, J. Am. Chem. Soc., vol. 52, 1930, pages 3456-3463. *
Mosettig E., et al, J. Am. Chem. Soc., vol. 53, 1931, pages 2295-2300. *
Piper J. R., J. Med Chem., vol. 9, 1966 pages 911-920. *
Taldukar P. B., et al, J. Org Chem., no. 24, 1959, pages 526-528. *
Traynham J. G., et al, Tetrahedron, vol. 7, 1959, pages 165-172. *

Also Published As

Publication number Publication date
CR7317A (es) 2006-08-09
US20070054950A1 (en) 2007-03-08
EP1440059A1 (en) 2004-07-28
OA12711A (en) 2006-06-27
MA27141A1 (fr) 2005-01-03
MY136580A (en) 2008-10-31
GT200200216A (es) 2003-05-23
BR0213464A (pt) 2004-11-09
PE20030610A1 (es) 2003-07-12
EA006708B1 (ru) 2006-02-24
SI1440059T1 (sl) 2008-08-31
ZA200402172B (en) 2006-09-27
HK1072052A1 (zh) 2005-08-12
GEP20084300B (en) 2008-02-11
EA200400467A1 (ru) 2004-08-26
IL161157A (en) 2009-09-01
AP1816A (en) 2008-01-04
US20050171178A1 (en) 2005-08-04
IS7187A (is) 2004-03-18
AR036905A1 (es) 2004-10-13
IL161157A0 (en) 2004-08-31
ATE392415T1 (de) 2008-05-15
CA2463264C (en) 2009-05-26
MXPA04003730A (es) 2004-07-23
JP2005511545A (ja) 2005-04-28
PT1440059E (pt) 2008-05-16
CN100368398C (zh) 2008-02-13
NZ531807A (en) 2006-03-31
PY0225353A (es) 2004-05-03
TNSN04071A1 (fr) 2006-06-01
KR20040048984A (ko) 2004-06-10
UA75714C2 (en) 2006-05-15
ES2302839T3 (es) 2008-08-01
JP4155522B2 (ja) 2008-09-24
AP2004003007A0 (en) 2004-06-30
EP1440059B1 (en) 2008-04-16
DK1440059T3 (da) 2008-07-14
SV2004001363A (es) 2004-02-24
CN1610664A (zh) 2005-04-27
NO20041626L (no) 2004-05-26
KR100621292B1 (ko) 2006-09-13
DE60226161D1 (de) 2008-05-29
DE60226161T2 (de) 2009-07-02
HN2002000299A (es) 2002-11-21
PL368919A1 (en) 2005-04-04
PA8556701A1 (es) 2003-07-28
RS25104A (sr) 2007-02-05
NO329092B1 (no) 2010-08-23
JP2008069169A (ja) 2008-03-27
ECSP045077A (es) 2004-05-28
US20030087898A1 (en) 2003-05-08
HRP20040288A2 (en) 2004-12-31
HUP0401884A2 (hu) 2005-01-28
WO2003035622A1 (en) 2003-05-01
US7049335B2 (en) 2006-05-23
CA2463264A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
CA2463264C (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
AU2002329557A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
USRE40838E1 (en) 2-azabicyclo[3.3.1]nonane derivatives
EP1483228B1 (en) Nk1 antagonists
JP2006522792A (ja) ４−フェニル−ピペリジン化合物およびそのオピオイド受容体のモジュレーターとしての使用
CA2522323C (en) 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
TW200526578A (en) Process for preparing an azabicyclo[3.1.0]hexane compound
HK1072052B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
HK1066787B (en) Nk1 antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired